Phase II Trial of Lung Chemoemobolization
NCT05672108
This study is recruiting at 2 US sites in 2 states, according to its ClinicalTrials.gov record last updated .
Summary
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases. TACE is a minimally invasive procedure that involves injecting chemotherapy directly into an artery that supplies blood to tumors, and then blocking off the blood supply to the tumors. Mitomycin (chemotherapy), Lipiodol (drug carrier), and Embospheres (small plastic beads that block off the artery) are injected into the tumor-feeding artery. This traps the chemotherapy inside the tumor and also cuts off the tumor\'s blood supply.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Lung Non-Small Cell Carcinoma
- Mediastinal Neoplasm
- Pleural Neoplasm
- Lung Metastases From Any Primary
- Endobronchial Metastases
- Colon Cancer
- Sarcoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- City of Hope Medical Center
- Last updated on ClinicalTrials.gov
- March 5, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- City of Hope Medical Center · Duarte, CA
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.